Abstract: Human Behavior Analysis (HBA) has emerged as a critical interdisciplinary field, combining psychology, sociology, artificial intelligence, and data science to model, understand, and predict ...
Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...
Want to Change Someone’s Behavior? Understand How the Brain Builds Habits, According to Neuroscience
The research, conducted at Georgetown University Medical Center, found that “shifting levels of a brain protein called KCC2 can reshape the way cues become linked with rewards, sometimes making habits ...
The new Wegovy pill was just approved in the US—and it’s the first oral GLP-1 for weight management on the market. Trials suggest it’s approximately as effective as the injectable form, and it has ...
The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. The full launch of the pill is expected in January.
The past 12 months had a little of everything — a career Grand Slam, Ryder Cup chaos and so much more. With 2026 on the horizon, our writers look back at the most memorable moments from 2025 and ...
The Food and Drug Administration has approved the first GLP-1 pill for weight loss, its manufacturer Novo Nordisk announced Monday, a milestone in the growth of the revolutionary drugs. The drug, a ...
The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...
The FDA has approved the first pill version of Wegovy, expanding access to one of the most popular and effective weight-loss medications in the U.S. The once-daily tablet offers a needle-free ...
Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...
WASHINGTON — Health officials worldwide are tracking a newly dominant influenza A strain, particularly a variant of H3N2 that has emerged earlier and spread more widely than usual this season, ...
Global X Cybersecurity ETF is upgraded to a Buy, with 24% upside potential by year-end 2026. BUG's portfolio rebalancing and additions like SailPoint and Rubrick have impacted recent performance, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback